Gain Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GANX research report →
Range $5 – $5
Price Chart
About the company
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments.
- CEO
- Gene Mack
- IPO
- 2021
- Employees
- 21
- HQ
- Bethesda, MD, US
Get TickerSpark's AI analysis on GANX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $42.63M
- P/E
- -2.50
- Fwd P/E
- 3.03
- PEG
- -0.06
- P/S
- 0.00
- P/B
- 4.53
- EV/EBITDA
- -1.93
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -133.17%
- ROIC
- -158.99%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,710,702
- Net Income
- $-20,161,099+1.2%
- EPS
- $-0.61+31.5%
- OCF Growth
- +2.2%
- FCF Growth
- +2.3%
- 52W High
- $4.34
- 52W Low
- $0.94
- 50D MA
- $1.40
- 200D MA
- $1.80
- Beta
- 0.19
- RSI (14)
- 39
- Avg Volume
- 550.22K
No earnings-call transcripts are available for GANX yet.
- Free Float
- 100.0%
- Shares Outstanding
- 42.65M
- Float Shares
- 42.64M
of shares held by institutions
54 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Marshall Wace, Llp | 1.68M | ▼ 242.74K |
| Potomac Capital Management, Inc. | 930.00K | ▼ 16.40K |
| Jones Financial Companies Lllp | 739.43K | ▲ 130.84K |
| Gsa Capital Partners Llp | 634.72K | ▲ 2.58K |
| Vanguard Group Inc | 569.90K | ▲ 35.55K |
| Cambridge Investment Research Advisors, Inc. | 566.64K | ▼ 2.00K |
| Dme Capital Management, LP | 566.13K | 0 |
| Vanguard Capital Management LLC | 480.27K | 0 |
| Geode Capital Management, LLC | 469.54K | ▲ 16.03K |
| Hohimer Wealth Management, LLC | 330.00K | ▲ 330.00K |
| Blackrock, Inc. | 268.32K | ▼ 6.64K |
| Ubs Group AG | 241.48K | ▲ 26.47K |
Held by 11 ETFs
Biggest fund positions in GANX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 29, 26 | Weidner Jeanette | other | 130,000 |
| Oct 28, 26 | Weidner Jeanette | other | 0 |
| Jul 15, 26 | GOLDSTEIN DOV A MD | other | 25,000 |
| Jul 15, 26 | Nicaise Claude | other | 25,000 |
| Jul 15, 26 | Islam Khalid | other | 25,000 |
| Jul 15, 26 | Melincoff Gwen A | other | 25,000 |
| Jul 15, 26 | Riley Jeffrey Scott | other | 25,000 |
| Jul 15, 26 | HASLER HANS PETER | other | 25,000 |
| Mar 24, 26 | Mack Gene | other | 200,000 |
| Mar 24, 26 | Fuggetta Gianluca | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GANX coverage
Recent articles, reports, and earnings notes.
No research on GANX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GANX report →Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
globenewswire.com · Nov 17
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
zacks.com · Nov 16
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
globenewswire.com · Nov 10
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
globenewswire.com · Nov 5
Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
globenewswire.com · Oct 13
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
globenewswire.com · Oct 8
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
globenewswire.com · Oct 1
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
globenewswire.com · Sep 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.